Paragraph 1 InterpretationF1
In this Schedule—
“end of trial date” is the date of the conclusion of the trial that is specified in the protocol of a clinical trial and which, in the case of a clinical trial conducted in other countries as well as the United Kingdom, is the end of the date of the trial in all the participating countries;
“the new rules” means these Regulations as in force on and after the relevant day;
“new rules clinical trial” means a clinical trial which is not an old rules clinical trial;
“old committee” means an ethics committee recognised under the old rules that has been abolished or has ceased to operate as an ethics committee for the purposes of these Regulations;
“the old rules” means these Regulations as in force immediately before the relevant day;
“old rules clinical trial” is to be construed in accordance with paragraph 2(1)(a);
“the relevant day” means the day on which this Schedule comes into force.
Where, by virtue of this Schedule, the old rules continue to apply, regulation 2 of the old rules applies to the interpretation of the old rules, except in so far as it is necessary for regulation 2 of the new rules to apply to their interpretation in order to give effect to a provision of this Schedule (for example, because a new committee is performing functions of an old committee).
For purposes of this Schedule, “sponsor”, in the context of the old rules, has the meaning given in regulation 3 of the old rules.
Regulation 53 of the new rules applies to both the new rules and the old rules.
Annotations
Textual amendments
- F1
Sch. 14 inserted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 45